Gibson Dunn Advised X4 Pharmaceuticals on Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Firm News | October 28, 2025
Gibson Dunn advised X4 Pharmaceuticals on its public offering of common stock and full exercise of the underwriters’ option to purchase additional shares for gross proceeds of $155.3 million.
Our corporate team was led by partners Ryan Murr, Branden Berns, and Melanie Neary and included associates Candice Johnson, Jasmine Vitug, and Anika Gidwani.